Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$68.98 ▼ $131.98	$14.05B	0.69	1.53 million shs	N/A
LGND Ligand Pharmaceuticals	$113.76 -0.7%	$108.41	$85.18 ▼ $129.90	$2.19B	0.84	118,079 shs	98,761 shs
RCKT Rocket Pharmaceuticals	$2.81 -3.1%	$4.50	$2.19 ▼ $26.98	$300.08M	0.67	2.22 million shs	2.45 million shs
XNCR Xencor	$7.94 -5.7%	$8.66	$7.16 ▼ $27.24	$565.09M	0.85	680,460 shs	564,037 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	0.00%	+89.58%
LGND Ligand Pharmaceuticals	0.00%	+0.21%	+7.92%	+15.06%	+35.58%
RCKT Rocket Pharmaceuticals	0.00%	+14.47%	-5.67%	-44.20%	-85.49%
XNCR Xencor	0.00%	+3.26%	-12.90%	+0.42%	-53.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	0.9328 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
LGND Ligand Pharmaceuticals	4.8008 of 5 stars	3.5	3.0	0.0	4.4	2.7	3.3	1.9
RCKT Rocket Pharmaceuticals	4.8147 of 5 stars	4.2	2.0	0.0	4.7	1.1	5.0	1.3
XNCR Xencor	3.9886 of 5 stars	3.4	2.0	0.0	3.9	1.9	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	28.47% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	561.92% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	252.64% Upside

Current Analyst Ratings Breakdown

Latest ITCI, XNCR, LGND, GBT, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
LGND Ligand Pharmaceuticals	$167.13M	13.13	$1.60 per share	71.31	$43.95 per share	2.59
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
XNCR Xencor	$110.49M	5.11	N/A	N/A	$9.63 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	30.66	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest ITCI, XNCR, LGND, GBT, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
8/4/2025	Q2 2025	XNCR Xencor	-$0.78	N/A	N/A	N/A	$22.59 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBT Global Blood Therapeutics	4.92	6.88	6.17
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBT Global Blood Therapeutics	N/A
ITCI Intra-Cellular Therapies	92.33%
LGND Ligand Pharmaceuticals	91.28%
RCKT Rocket Pharmaceuticals	98.39%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
GBT Global Blood Therapeutics	4.90%
ITCI Intra-Cellular Therapies	2.60%
LGND Ligand Pharmaceuticals	7.00%
RCKT Rocket Pharmaceuticals	24.76%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
XNCR Xencor	280	71.17 million	67.45 million	Optionable

ITCI, XNCR, LGND, GBT, and RCKT Headlines

Recent News About These Companies

Xencor, Inc. (NASDAQ:XNCR) Receives $28.00 Consensus PT from Brokerages

July 6 at 3:45 AM | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

July 3, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling

June 17, 2025 | marketbeat.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 16, 2025 | marketbeat.com

Kurt A. Gustafson Sells 2,993 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Ellen Feigal Sells 2,993 Shares

June 16, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10, 2025 | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITCI, XNCR, LGND, GBT, and RCKT Company Descriptions

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Ligand Pharmaceuticals NASDAQ:LGND

$113.76 -0.82 (-0.72%)

As of 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.81 -0.09 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.83 +0.02 (+0.71%)

As of 07:44 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Xencor NASDAQ:XNCR

$7.94 -0.48 (-5.70%)

As of 04:00 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time